|
Osiris Therapeutics, Inc., based in Columbia, Maryland, is the world leader in researching, developing and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world’s first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4 , Cartiform and Grafix. Osiris, Grafix, and Cartiform are registered trademarks of Osiris Therapeutics, Inc. BIO4 is a trademark of Stryker Corporation (NYSE: SYK). More information can be found on the company's website, www.Osiris.com. (OSIR-G) The company is led by Lode Debrabandere, Ph.D., President and Chief Executive officer. The company was founded based on research by Dr. Arnold Caplan at Case Western University. It was co-founded by Peter Friedli and Kevin Kimberlin in 1992. In 2006, Osiris completed its IPO on Nasdaq under the symbol OSIR. In 2014, Osiris transformed into a fully integrated company by commercializing its product portfolio. The three pillars, innovation, differentiation, and transformation, define the culture at Osiris. ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Osiris Therapeutics」の詳細全文を読む スポンサード リンク
|